By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name McKesson Corporation
Stock ticker MCK
Live stock price [stckqut]MCK[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Fair
EPS growth Poor
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $310.15
Target stock price (averages with growth) $353.01
Target stock price (averages with no growth) $164.7
Target stock price (manual assumptions) $305.8

The following company description is from Google Finance: http://www.google.com/finance?q=mck

McKesson Corporation delivers pharmaceuticals, medical supplies and healthcare information technologies. The Company operates in two segments: McKesson Distribution Solutions segment and McKesson Technology Solutions segment. The McKesson Distribution Solutions segment distributes drugs, medical-surgical supplies and equipment and health and beauty care products throughout North America. The McKesson Technology Solutions segment delivers enterprise clinical, patient care, financial, supply chain, strategic management software solutions, pharmacy automation for hospitals, as well as connectivity, outsourcing and other services, including remote hosting and managed services, to healthcare organizations. In February 2013, the Company completed acquisition of Pss World Medical Inc. In February 2014, McKesson Corporation announced that its ownership in Celesio AG exceeds 75% interest.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in McKesson Corporation.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of McKesson Corporation calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $210.99
  • Growth: 0.19
  • Current EPS (TTM): $6.07
  • P/E: 34
  • Future EPS Calc: $14.48
  • Future Stock Price Calc: $492.49
  • Target stock price: $305.8

I hope that this makes you a better investor. [/s2If]

By:
On:
In: Poor company, Stock analysis
With: 0 Comments

 

Company name Intrexon Corp
Stock ticker XON
Live stock price [stckqut]XON[/stckqut]
Confident Investor Rating Poor

The following company description is from Google Finance: http://www.google.com/finance?q=xon

Intrexon Corporation is engaged in the business of synthetic biology. Using the Company’s suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. In March 2014, the Company acquired Medistem, Inc. In March 2014, Intrexon Corp acquired laboratory operations in Budapest, Hungary from Codexis, Inc. In August 2014, it acquired Trans Ova Genetics, L.C.

Confident Investor comments: At this price and at this time, I do not think that a Confident Investor can confidently invest in Intrexon Corp. It is not possible to confidently invest in a company that is not currently profitable.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

By:
On:
In: Fair company, Stock analysis
With: 0 Comments

Company name Towers Watson & Co
Stock ticker TW
Live stock price [stckqut]TW[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Poor
EPS growth Poor
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $116.2
Target stock price (averages with growth) $97.68
Target stock price (averages with no growth) $53.2
Target stock price (manual assumptions) $107.9

The following company description is from Google Finance: http://www.google.com/finance?q=tw

Towers Watson & Co. (Towers Watson) is a global professional services company. The Company offers solutions in the areas of benefits, talent management, rewards, and risks and capital management. The Company offers its clients comprehensive services across four business segments: Benefits, Risk and Financial Services, Talent and Rewards, and exchanges Solutions. The Company delivers consulting services and solutions, which help organizations, anticipate, identify and capitalize on emerging opportunities in benefit and human capital management. The Company advises the insurance industry on a range of strategic and risks management issues, and the Company helps its clients in all industries mitigate risk through insurance, reinsurance and capital markets transactions. In November 2013, Towers Watson and Co announced the completion of its sale of the Company’s reinsurance brokerage business to Jardine Lloyd Thompson Group plc. In November 2013, the Company acquired Liazon Corporation.

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in Towers Watson & Co as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Towers Watson & Co calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $112.97
  • Growth: 0.12
  • Current EPS (TTM): $4.93
  • P/E: 20
  • Future EPS Calc: $8.68
  • Future Stock Price Calc: $173.76
  • Target stock price: $107.89

I hope that this makes you a better investor. [/s2If]

By:
On:
In: Fair company, Stock analysis
Tagged:
With: 0 Comments

Company name Universal Health Services, Inc.
Stock ticker UHS
Live stock price [stckqut]UHS[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Poor
EPS growth Poor
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $100.07
Target stock price (averages with growth) $96.75
Target stock price (averages with no growth) $53.07
Target stock price (manual assumptions) $108.33

The following company description is from Google Finance: http://www.google.com/finance?q=uhs

Universal Health Services, Inc., owns and operates through its subsidiaries, acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers and radiation oncology centers. As of February 28, 2013, it owned and/or operated 23 acute care hospitals and 197 behavioral health centers located in 37 states, Washington, D.C., Puerto Rico and the United States, Virgin Islands. As part of its ambulatory treatment centers division, it manages and/or own outright or in partnerships with physicians, five surgical hospitals and surgery and radiation oncology centers located in four states. In April 2014, it completed the acquisition of the Psychiatric Institute of Washington (PIW), a 124-bed behavioral health care facility and outpatient treatment center located in the District of Columbia. It has added a total of 17 facilities throughout the United Kingdom including 15 inpatient behavioral health hospitals and two nursing homes with a total of 743 beds.

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in Universal Health Services, Inc. as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Universal Health Services, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $98.79
  • Growth: 0.12
  • Current EPS (TTM): $4.95
  • P/E: 20
  • Future EPS Calc: $8.72
  • Future Stock Price Calc: $174.47
  • Target stock price: $108.33

I hope that this makes you a better investor. [/s2If]

By:
On:
In: Fair company, Stock analysis
With: 0 Comments

 

Company name Westlake Chemical Corporation
Stock ticker WLK
Live stock price [stckqut]WLK[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Fair
EPS growth Poor
P/E growth Poor
EBIT growth Good

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $83.06
Target stock price (averages with growth) $77.3
Target stock price (averages with no growth) $38.68
Target stock price (manual assumptions) $70.2

The following company description is from Google Finance: http://www.google.com/finance?q=wlk

Westlake Chemical Corporation, is a vertically integrated manufacturer and marketer of basic chemicals, vinyls, polymers and fabricated building products. The Company’s products include some of the widely used chemicals in the world, which are fundamental to many diverse consumer and industrial markets, including flexible and rigid packaging, automotive products, coatings, residential and commercial construction as well as other durable and non-durable goods. In July 2014, the Company acquired Vinnolit Holdings GmbH and its subsidiary companies from Advent International. In July 2014, Westlake Chemical Corp acquired Vinnolit Holdings GmbH, an Ismaning-based manufacturer of polyvinyl chloride (PVC).

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in Westlake Chemical Corporation as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Westlake Chemical Corporation calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $67.73
  • Growth: 0.11
  • Current EPS (TTM): $4.97
  • P/E: 13.5
  • Future EPS Calc: $8.37
  • Future Stock Price Calc: $113.05
  • Target stock price: $70.2

I hope that this makes you a better investor. [/s2If]